AB Science SA (AB) AI Stock Analysis

• Market Cap: €89.22M
• Dividend Yield: N/A
• Average Volume (3M): 323.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -5.08%
• EPS Growth: -88.04%
• Country: FR
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 66,184,790
• 10 Day Avg. Volume: 89,975
• 30 Day Avg. Volume: 323,750
• PEG Ratio: 0.16
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 43.83
• P/FCF Ratio: 127.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.13
• Revenue Forecast (FY): €1.10M

• Rating: 40 Neutral
• Price Target: €1.50 ▲(1.35% Upside)
• Action: Reiterated Date: 11/06/25
• Date: Action: Reiterated 11/06/25

AB Science SA's overall stock score is primarily impacted by its poor financial performance and negative valuation metrics. The technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Proprietary drug platform

A proprietary protein kinase inhibitor platform focused on oncology and neurology provides durable R&D leverage. Platform assets can produce multiple candidates, increase licensing and partnership optionality, and create long-term differentiation if clinical progress continues.

Improving operating cash flow

Transition to positive operating and free cash flow in 2024 indicates improving cash generation capacity. Sustained cash generation reduces immediate financing needs, supports ongoing clinical programs, and materially lengthens runway versus firms reliant solely on external funding.

Lean cost structure

A small workforce (40 employees) suggests a lean operating model that can limit fixed overhead and conserve cash. For an R&D-focused biotech, lower structural burn improves capital efficiency and makes incremental financing requirements smaller and more manageable over time.

Negative Factors

Negative shareholders' equity

Negative shareholders' equity is a persistent solvency flag: liabilities exceed assets, impairing borrowing capacity and covenant flexibility. This structural weakness raises long-term refinancing and counterparty risk, potentially constraining growth and strategic options.

Persistent operating losses

Ongoing negative EBIT and net loss reflect structural unprofitability from operations. Continued operating deficits will necessitate repeated capital raises or partnerships, undermine retained earnings, and make it harder to finance late-stage trials or commercialization without dilution.

Reliance on financing activities

Dependence on external financing to fund operations is a durable risk: access to capital can fluctuate and dilutes existing holders. Long-term reliance raises cost of capital, increases execution risk for clinical programs, and can interrupt development timelines if markets tighten.

AB Science SA Business Overview & Revenue Model

Company Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

How the Company Makes Money

AB Science generates revenue primarily through the development and commercialization of its pharmaceutical products. The company focuses on advancing its drug candidates through clinical trials, and once approved, it can either sell these products directly or partner with larger pharmaceutical companies for distribution. Key revenue streams include sales from marketed drugs, milestone payments from partnerships, and royalties on sales of partnered products. Significant partnerships with established pharmaceutical companies can enhance AB Science's market reach and financial stability, providing additional income through collaborations and shared research initiatives. Furthermore, the company may also benefit from grants and funding for innovative research projects that align with its therapeutic focus.

AB Science SA Financial Statement Overview

Summary

AB Science SA faces significant financial challenges with negative equity, persistent operating losses, and reliance on financing activities. Despite slight improvements in cash flow and revenue growth, the company remains unprofitable, reflecting instability and high financial risk.

Income Statement

The income statement shows a challenging financial position for AB Science SA. Despite a slight increase in revenue in 2024, the company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. The gross profit margin has improved, but net profit margins are significantly negative due to high operating losses. Revenue growth is positive but modest, and the company remains unprofitable, reflecting instability in its revenue generation and cost management.

Balance Sheet

AB Science SA's balance sheet reveals significant financial risk with negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio cannot be calculated due to negative equity, highlighting potential solvency concerns. While the cash balance is relatively stable, total liabilities consistently exceed total assets, reflecting a leveraged position and financial instability.

Cash Flow

The cash flow statement indicates some improvement in cash flow management in 2024, with positive operating cash flow and free cash flow. However, historical data shows persistent negative free cash flow, indicating challenges in generating sufficient cash from operations. The free cash flow to net income ratio is not meaningful due to negative net income. The company's reliance on financing activities to support cash flow is evident, suggesting potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	1.07M	970.00K	958.00K	1.61M	1.58M
Gross Profit	1.13M	1.25M	587.00K	927.00K	1.50M	1.51M
EBITDA	-4.47M	-4.92M	-12.80M	-13.41M	-17.36M	-17.10M
Net Income	-8.54M	-7.83M	-10.05M	-13.62M	-14.46M	-15.04M
Balance Sheet
Total Assets	21.22M	23.18M	25.50M	23.84M	21.27M	29.69M
Cash, Cash Equivalents and Short-Term Investments	5.03M	7.99M	6.07M	7.27M	8.72M	20.66M
Total Debt	19.08M	18.47M	19.10M	23.96M	8.35M	7.06M
Total Liabilities	48.54M	46.93M	46.51M	59.51M	44.47M	49.24M
Stockholders Equity	-27.32M	-23.75M	-21.01M	-35.67M	-23.20M	-19.55M
Cash Flow
Free Cash Flow	-7.08M	370.00K	-17.22M	-18.11M	-17.74M	-13.88M
Operating Cash Flow	-6.88M	525.00K	-16.87M	-17.47M	-17.18M	-13.51M
Investing Cash Flow	-189.00K	-136.00K	-614.00K	-360.00K	-590.00K	-277.00K
Financing Cash Flow	2.97M	1.53M	16.27M	16.39M	5.84M	28.73M

AB Science SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.37, and above the 200-day MA of 1.29, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 76.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AB.

AB Science SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALSEN	55 Neutral	€169.86M	-3.53	-40.00%	―	―	10.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSE	49 Neutral	€95.33M	-2.78	-52.76%	―	-96.92%	-175.84%
IPH	47 Neutral	€139.65M	-2.70	-271.32%	―	-75.86%	-30.54%
TNG	43 Neutral	€224.05M	-3.24	―	―	111.76%	-22.45%
AB	40 Neutral	€89.22M	-9.08	―	―	-5.08%	-88.04%